Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1996 1
1997 1
1999 1
2000 1
2001 6
2002 1
2003 6
2004 3
2005 6
2006 2
2007 5
2008 5
2009 6
2010 3
2011 5
2012 5
2013 11
2014 7
2015 9
2016 10
2017 11
2018 5
2019 11
2020 10
2021 18
2022 18
2023 22
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for anti i. Papadopoulou
Your search for Anthi I. Papadopoulou retrieved no results
Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016).
Jones NL, Koletzko S, Goodman K, Bontems P, Cadranel S, Casswall T, Czinn S, Gold BD, Guarner J, Elitsur Y, Homan M, Kalach N, Kori M, Madrazo A, Megraud F, Papadopoulou A, Rowland M; ESPGHAN, NASPGHAN. Jones NL, et al. J Pediatr Gastroenterol Nutr. 2017 Jun;64(6):991-1003. doi: 10.1097/MPG.0000000000001594. J Pediatr Gastroenterol Nutr. 2017. PMID: 28541262
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
Results from a phase 2 study suggested that eculizumab, a terminal complement inhibitor, produced clinically meaningful improvements in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis. ...
Results from a phase 2 study suggested that eculizumab, a terminal complement inhibitor, produced clinically meaningful improvements in pati …
Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.
Vakrakou AG, Karachaliou E, Chroni E, Zouvelou V, Tzanetakos D, Salakou S, Papadopoulou M, Tzartos S, Voumvourakis K, Kilidireas C, Giannopoulos S, Tsivgoulis G, Tzartos J. Vakrakou AG, et al. Front Immunol. 2023 Jul 26;14:1212757. doi: 10.3389/fimmu.2023.1212757. eCollection 2023. Front Immunol. 2023. PMID: 37564637 Free PMC article. Review.
Reduction of antibody titers follows the clinical efficacy of anti-CD20 therapies, a feature implying the role of short-lived plasma cells (SLPB) in autoantibody production. ...
Reduction of antibody titers follows the clinical efficacy of anti-CD20 therapies, a feature implying the role of short-lived plasma …
Efficacy and safety of emapalumab in macrophage activation syndrome.
De Benedetti F, Grom AA, Brogan PA, Bracaglia C, Pardeo M, Marucci G, Eleftheriou D, Papadopoulou C, Schulert GS, Quartier P, Antón J, Laveille C, Frederiksen R, Asnaghi V, Ballabio M, Jacqmin P, de Min C. De Benedetti F, et al. Ann Rheum Dis. 2023 Jun;82(6):857-865. doi: 10.1136/ard-2022-223739. Epub 2023 Mar 31. Ann Rheum Dis. 2023. PMID: 37001971 Free PMC article.
The efficacy outcome was MAS remission by week 8, based on clinical and laboratory criteria. METHODS: We studied emapalumab, a human anti-IFNgamma antibody, administered with background glucocorticoids, in a prospective single-arm trial involving patients who had MAS secon …
The efficacy outcome was MAS remission by week 8, based on clinical and laboratory criteria. METHODS: We studied emapalumab, a human anti …
The Relationship of Ketogenic Diet with Neurodegenerative and Psychiatric Diseases: A Scoping Review from Basic Research to Clinical Practice.
Mentzelou M, Dakanalis A, Vasios GK, Gialeli M, Papadopoulou SK, Giaginis C. Mentzelou M, et al. Nutrients. 2023 May 11;15(10):2270. doi: 10.3390/nu15102270. Nutrients. 2023. PMID: 37242153 Free PMC article. Review.
In the last few decades, the current re-emergence of its popularity has focused on the treatment of obesity and diabetes mellitus. KD also exerts anti-inflammatory and neuroprotective properties, which could be utilized for the therapy of neurodegenerative and psychiatric …
In the last few decades, the current re-emergence of its popularity has focused on the treatment of obesity and diabetes mellitus. KD also e …
The Olympia Declaration.
Pitsiladis YP, Abatzis-Papadopoulos M, Ali N, Aggeloudis S, Atkinson C, Constandache B, Ganus Y, Geladas N, Giakoumakis SI, Güner R, Howman D, Lima GHO, Khristenko E, Koskolou M, Klissouras V, Ladikas M, Loland S, McNamee MJ, Pardos BM, Natsis K, Nicholson P, Betancurt JO, Angeloudis K, Pappas E, Peteraitis M, Petróczi A, Papadopoulou T, Pigozzi F, Saugy M, Simon P, Singleton P, Sizikova E, Sottas PE, Tanaka M, Wang G, Yang H. Pitsiladis YP, et al. Curr Sports Med Rep. 2019 Dec;18(12):448-451. doi: 10.1249/JSR.0000000000000660. Curr Sports Med Rep. 2019. PMID: 31834176 No abstract available.
Calprotectin in Lung Diseases.
Kotsiou OS, Papagiannis D, Papadopoulou R, Gourgoulianis KI. Kotsiou OS, et al. Int J Mol Sci. 2021 Feb 8;22(4):1706. doi: 10.3390/ijms22041706. Int J Mol Sci. 2021. PMID: 33567747 Free PMC article. Review.
CLP is involved in numerous cellular processes in lung health and disease. In addition to its anti-microbial functions, CLP also serves as a molecule with pro- and anti-tumor properties related to cell survival and growth, angiogenesis, DNA damage response, and the …
CLP is involved in numerous cellular processes in lung health and disease. In addition to its anti-microbial functions, CLP also serv …
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, Amil Dias J, Barabino A, Braegger CP, Bronsky J, Buderus S, Martín-de-Carpi J, De Ridder L, Fagerberg UL, Hugot JP, Kierkus J, Kolacek S, Koletzko S, Lionetti P, Miele E, Navas López VM, Paerregaard A, Russell RK, Serban DE, Shaoul R, Van Rheenen P, Veereman G, Weiss B, Wilson D, Dignass A, Eliakim A, Winter H, Turner D; European Crohn's and Colitis Organisation; European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Ruemmele FM, et al. J Crohns Colitis. 2014 Oct;8(10):1179-207. doi: 10.1016/j.crohns.2014.04.005. Epub 2014 Jun 6. J Crohns Colitis. 2014. PMID: 24909831 Free article.
The experts discuss several factors potentially predictive for poor disease outcome (such as severe perianal fistulizing disease, severe stricturing/penetrating disease, severe growth retardation, panenteric disease, persistent severe disease despite adequate induction therapy), …
The experts discuss several factors potentially predictive for poor disease outcome (such as severe perianal fistulizing disease, severe str …
Daclizumab for the treatment of multiple sclerosis.
Papadopoulou A, Derfuss T, Sprenger T. Papadopoulou A, et al. Neurodegener Dis Manag. 2017 Oct;7(5):279-297. doi: 10.2217/nmt-2017-0023. Epub 2017 Aug 29. Neurodegener Dis Manag. 2017. PMID: 28849702 Review.
173 results